Risk of arrhythmic death in ischemic heart disease: a prospective, controlled, observer-blind risk stratification over 10 years

European Journal of Clinical Investigation

Volumn 47, Issue 3, 2017, Pages 231-240

  Pezawas, Thomas ^a   Diedrich, André ^b   Robertson, David ^b   Winker, Robert ^c   Richter, Bernhard ^a   Wang, Li ^d   Schmidinger, Herwig ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c Health and Prevention Center   (Austria)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ischemic heart disease; non invasive risk stratification; sudden cardiac death

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARRHYTHMIC DEATH; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; EXERCISE; FEMALE; FOLLOW UP; HEART ARREST; HEART ARRHYTHMIA; HEART DEATH; HEART FUNCTION TEST; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE VARIABILITY; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MICROVOLT T WAVE ALTERNAN; PATIENT RISK; PHARMACOLOGICAL BAROREFLEX TESTING; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESUSCITATION; RISK ASSESSMENT; RISK FACTOR; SHORT COURSE THERAPY; T WAVE; TREATMENT DURATION; ARRHYTHMIAS, CARDIAC; CASE CONTROL STUDY; COMPLICATION; DEATH, SUDDEN, CARDIAC; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART RATE; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; SINGLE BLIND PROCEDURE; TIME FACTOR;

ADULT; AGED; ARRHYTHMIAS, CARDIAC; CASE-CONTROL STUDIES; DEATH, SUDDEN, CARDIAC; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROSPECTIVE STUDIES; RISK ASSESSMENT; SINGLE-BLIND METHOD; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85012041112     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12729     Document Type: Article

References (18)

1. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933–40.
2. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999;341:1882–90.
3. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–83.
4. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998;351:478–84.
5. Bloomfield DM, Steinman RC, Namerow PB, Parides M, Davidenko J, Kaufman ES et al. Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: a solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II conundrum. Circulation 2004;110:1885–9.
6. Gold MR, Bloomfield DM, Anderson KP, El-Sherif NE, Wilber DJ, Groh WJ et al. A comparison of T-wave alternans, signal averaged electrocardiography and programmed ventricular stimulation for arrhythmia risk stratification. J Am Coll Cardiol 2000;36:2247–53.
7. Exner DV, Kavanagh KM, Slawnych MP, Mitchell LB, Ramadan D, Aggarwal SG et al. Noninvasive risk assessment early after a myocardial infarction the REFINE study. J Am Coll Cardiol 2007;50:2275–84.
8. Pezawas T, Stix G, Kastner J, Schneider B, Wolzt M, Schmidinger H. Ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy: clinical presentation, risk stratification and results of long-term follow-up. Int J Cardiol 2006;107:360–8.
9. Pezawas T, Stix G, Kastner J, Wolzt M, Mayer C, Moertl D et al. Unexplained syncope in patients with structural heart disease and no documented ventricular arrhythmias: value of electrophysiologically guided implantable cardioverter defibrillator therapy. Europace, 2003;5:305–12.
10. Gratze G, Fortin J, Holler A, Grasenick K, Pfurtscheller G, Wach P et al. A software package for non-invasive, real-time beat-to-beat monitoring of stroke volume, blood pressure, total peripheral resistance and for assessment of autonomic function. Comput Biol Med 1998;28:121–42.
11. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 1996;17:354–81.
12. Hinkle LE Jr, Thaler HT. Clinical classification of cardiac deaths. Circulation 1982;65:457–64.
13. Pezawas T, Diedrich A, Winker R, Robertson D, Richter B, Wang L et al. Multiple autonomic and repolarization investigation of sudden cardiac death in dilated cardiomyopathy and controls. Circ Arrhythm Electrophysiol 2014;7:1101–8.
14. Russo AM, Stainback RF, Bailey SR, Epstein AE, Heidenreich PA, Jessup M et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol, 2013;61:1318–68.
15. Bigger JT Jr, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984;69:250–8.
16. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225–37.
17. Huikuri HV, Raatikainen MJ, Moerch-Joergensen R, Hartikainen J, Virtanen V, Boland J et al. Prediction of fatal or near-fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocardial infarction. Eur Heart J, 2009;30:689–98.
18. Huikuri HV, Tapanainen JM, Lindgren K, Raatikainen P, Makikallio TH, Juhani Airaksinen KE et al. Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2003;42:652–8.